Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP8 | P40818 | 17/20 | 1.00 |
| ▸ | USP7 | Q93009 | 11/20 | 0.61 |
| ▸ | USP47 | Q96K76 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599545 | 0.88 | USP8 (0.78) | USP8USP7USP47MAPTMAPK1 | |
| SCHEMBL30931160 | 0.76 | USP8 (1.00) | USP8USP7USP47MAPTRAB9A | |
| SCHEMBL1512485 | 0.76 | USP8 (1.00) | USP8USP7USP47MAPTRAB9A | |
| SCHEMBL1512505 | 0.76 | USP8 (1.00) | USP8USP7USP47 | |
| SCHEMBL1512515 | 0.76 | USP8 (0.92) | USP8USP7USP47MAPTRAB9A | |
| SCHEMBL7984632 | 0.75 | USP8 (0.60) | USP8USP7MAPTMAPK1RAB9A | |
| SCHEMBL8487532 | 0.73 | USP8 (0.78) | USP8USP7USP47MAPTRAB9A | |
| SCHEMBL14560968 | 0.71 | USP8 (0.55) | USP8MAPK1RAB9A | |
| SCHEMBL1512466 | 0.71 | USP8 (1.00) | USP8USP7USP47RAB9A | |
| SCHEMBL1512378 | 0.70 | USP8 (1.00) | USP8USP7USP47MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648076-B2 | Cysteine protease inhibitors and their therapeutic applications | HYBRIGENICS SA (FR) | 2014-02-11 | — | — | US | claimed |
| EP-1912954-B1 | NOVEL CYSTEINE PROTEASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2011-03-09 | — | — | EP | claimed |
| US-20090215786-A1 | NOVEL CYSTEINE PROTEASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2009-08-27 | — | — | US | claimed |
| EP-1749822-B1 | Novel cysteine protease inhibitors and their therapeutic applications | HYBRIGENICS SA (FR) | 2008-10-15 | — | — | EP | claimed |
| EP-1749822-A1 | Novel cysteine protease inhibitors and their therapeutic applications | Hybrigenics S.A. (FR) | 2007-02-07 | — | — | EP | claimed |
| US-8648076-B2 | Cysteine protease inhibitors and their therapeutic applications | HYBRIGENICS SA (FR) | 2014-02-11 | — | — | US | disclosed |
| US-8648076-B2 | Cysteine protease inhibitors and their therapeutic applications | HYBRIGENICS SA (FR) | 2014-02-11 | — | — | US | disclosed |
| US-8648076-B2 | Cysteine protease inhibitors and their therapeutic applications | HYBRIGENICS SA (FR) | 2014-02-11 | — | — | US | disclosed |
| EP-1912954-B1 | NOVEL CYSTEINE PROTEASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2011-03-09 | — | — | EP | disclosed |
| US-20090215786-A1 | NOVEL CYSTEINE PROTEASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090215786-A1 | NOVEL CYSTEINE PROTEASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090215786-A1 | NOVEL CYSTEINE PROTEASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2009-08-27 | — | — | US | disclosed |
| EP-1749822-B1 | Novel cysteine protease inhibitors and their therapeutic applications | HYBRIGENICS SA (FR) | 2008-10-15 | — | — | EP | disclosed |
| EP-1912954-A2 | NOVEL CYSTEINE PROTEASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | Hybrigenics S.A. (FR) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007017758-A2 | NOVEL CYSTEINE PROTEASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032499-A1 | Novel cysteine protease inhibitors and their therapeutic applications | HYBRIGENICS SA (FR) | 2007-02-08 | — | — | US | disclosed |
| US-20070032499-A1 | Novel cysteine protease inhibitors and their therapeutic applications | HYBRIGENICS SA (FR) | 2007-02-08 | — | — | US | disclosed |
| US-20070032499-A1 | Novel cysteine protease inhibitors and their therapeutic applications | HYBRIGENICS SA (FR) | 2007-02-08 | — | — | US | disclosed |
| EP-1749822-A1 | Novel cysteine protease inhibitors and their therapeutic applications | Hybrigenics S.A. (FR) | 2007-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032499-A1 | Novel cysteine protease inhibitors and their therapeutic applications | SERPINB1, CTSF, CTSE | USP8 197/4885USP7 205/4885USP47 178/4885 |
| US-20090215786-A1 | NOVEL CYSTEINE PROTEASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | SERPINB1, CTSF, CTSE | USP8 197/4885USP7 205/4885USP47 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.